Ligand Pharmaceuticals Inc. (Nasdaq: LGND) Wednesday reported total revenues for the first quarter of 2014 increased 37 percent to $16 million, compared with the first quarter of 2013.
The company's royalty revenues increased 35 percent to $7.9 million, and its non-GAAP net income from continuing operations was $0.35 per diluted share.
Ligand also reported its net income increased 40 percent in the first three months ended March 31, 2014, from the same period a year ago to $2.1 million, or $0.10 per diluted share.
Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.
SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.
All contents herein copyright San Diego Source ® 1994-2015